Literature DB >> 11282984

Dendritic cells infected with Mycobacterium bovis bacillus Calmette Guerin activate CD8(+) T cells with specificity for a novel mycobacterial epitope.

C G Feng1, C Demangel, A T Kamath, M Macdonald, W J Britton.   

Abstract

Although CD4(+) T cells are essential for protective immunity against Mycobacterium tuberculosis infection, recent reports indicate that CD8(+) T cells may also play a critical role in the control of this infection. However, the epitope specificity and the mechanisms of activation of mycobacteria-reactive CD8(+) T cells are poorly characterized. In order to study the CD8(+) T cell responses to the model mycobacterial antigen, MPT64, we used recombinant vaccinia virus expressing MPT64 (VVWR-64) and a panel of MPT64-derived peptides to establish that the peptide MPT64(190-198) contains an H-2D(b)-restricted CD8(+) T cell epitope. A cytotoxic T lymphocyte response to this peptide could be demonstrated in M. bovis bacillus Calmette Guerin (BCG)-infected mice following repeated in vitro stimulation. When bone marrow-derived dendritic cells (DC) were infected with BCG, the expression of MHC class I molecules by DC was up-regulated in parallel with MHC class II and B7-2, whereas CD1d expression level was not modified. Moreover, BCG-infected DC activated MPT64(190-198)-specific CD8(+) T cells to secrete IFN-gamma, although with a lower efficacy than VVWR-64-infected DC. The production of IFN-gamma by MPT64(190-198)-specific CD8(+) T cells was inhibited by antibodies to MHC class I, but not to CD1d. These data suggest that mycobacteria-specific CD8(+) T cells are primed during infection. Therefore, anti-mycobacterial vaccine strategies targeting the activation of specific CD8(+) T cells by DC may have improved protective efficacy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11282984     DOI: 10.1093/intimm/13.4.451

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  10 in total

1.  Coexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobacterium tuberculosis.

Authors:  Umaimainthan Palendira; Arun T Kamath; Carl G Feng; Ela Martin; Paul J Chaplin; James A Triccas; Warwick J Britton
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

Review 2.  Immunological control of tuberculosis: role of tumour necrosis factor and more.

Authors:  S Stenger
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 3.  Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity.

Authors:  Joshua S M Woodworth; Samuel M Behar
Journal:  Crit Rev Immunol       Date:  2006       Impact factor: 2.214

4.  CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family.

Authors:  Laleh Majlessi; Marie-Jésus Rojas; Priscille Brodin; Claude Leclerc
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

5.  Mycobacterium bovis bacillus Calmette-Guérin-infected dendritic cells potently activate autologous T cells via a B7 and interleukin-12-dependent mechanism.

Authors:  Eleanor J Cheadle; Peter J Selby; Andrew M Jackson
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

6.  Mycobacterium leprae infection in monocyte-derived dendritic cells and its influence on antigen-presenting function.

Authors:  Ken Hashimoto; Yumi Maeda; Hiroaki Kimura; Koichi Suzuki; Akihiro Masuda; Masanori Matsuoka; Masahiko Makino
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

7.  Cytolytic CD8+ T cells recognizing CFP10 are recruited to the lung after Mycobacterium tuberculosis infection.

Authors:  Arati B Kamath; Joshua Woodworth; Xiaowei Xiong; Chad Taylor; Yu Weng; Samuel M Behar
Journal:  J Exp Med       Date:  2004-11-22       Impact factor: 14.307

Review 8.  Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-α reagents.

Authors:  Kozo Yasui
Journal:  Pediatr Rheumatol Online J       Date:  2014-10-02       Impact factor: 3.054

9.  Mycobacterium smegmatis Vaccine Vector Elicits CD4+ Th17 and CD8+ Tc17 T Cells With Therapeutic Potential to Infections With Mycobacterium avium.

Authors:  Nisha Kannan; Markus Haug; Magnus Steigedal; Trude Helen Flo
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

10.  CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.

Authors:  Tara Elvang; Jan P Christensen; Rolf Billeskov; Truc Thi Kim Thanh Hoang; Peter Holst; Allan Randrup Thomsen; Peter Andersen; Jes Dietrich
Journal:  PLoS One       Date:  2009-04-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.